Loss of Raltegravir Susceptibility by Human Immunodeficiency Virus Type 1 Is Conferred via Multiple Nonoverlapping Genetic Pathways

ABSTRACT The human immunodeficiency virus type 1 (HIV-1) integrase mutations N155H and Q148R(H)(K) that reduce susceptibility to the integrase inhibitor raltegravir have been identified in patients failing treatment regimens containing raltegravir. Whether these resistance mutations occur individually or in combination within a single virus genome has not been defined, nor do we fully understand the impact of these primary mutations and other secondary mutations on raltegravir susceptibility and viral replication capacity. To address these important questions, we investigated the raltegravir susceptibility and replication capacity of viruses containing mutations at positions 155 and 148 separately or in combination with secondary mutations selected in subjects failing treatment regimens containing raltegravir. Clonal analysis demonstrated that N155H and Q148R(H)(K) occur independently, not in combination. Viruses containing a Q148R(H)(K) mutation generally displayed larger reductions in raltegravir susceptibility than viruses with an N155H mutation. Analysis of site-directed mutants indicated that E92Q in combination with N155H resulted in a higher level of resistance to raltegravir than N155H alone. Viruses containing a Q148R(H) mutation together with a G140S mutation were more resistant to raltegravir than viruses containing a Q148R(H) mutation alone; however, viruses containing G140S and Q148K were more susceptible to raltegravir than viruses containing a Q148K mutation alone. Both N155H and Q148R(H)(K) mutations reduced the replication capacity, while the addition of secondary mutations either improved or reduced the replication capacity depending on the primary mutation. This study demonstrates distinct genetic pathways to resistance in subjects failing raltegravir regimens and defines the effects of primary and secondary resistance mutations on raltegravir susceptibility and replication capacity.

[1]  R. Danovich,et al.  Selection and analysis of HIV-1 integrase strand transfer inhibitor resistant mutant viruses. , 2009, Methods.

[2]  E. Garvey,et al.  Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics. , 2009, Antiviral research.

[3]  Anders Karlsson,et al.  Maraviroc for previously treated patients with R5 HIV-1 infection. , 2008, The New England journal of medicine.

[4]  C. Charpentier,et al.  Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy * , 2008, HIV medicine.

[5]  K. Hertogs,et al.  Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors , 2008, Journal of Virology.

[6]  Tommy F. Liu,et al.  Natural variation of HIV-1 group M integrase: Implications for a new class of antiretroviral inhibitors , 2008, Retrovirology.

[7]  D. Hazuda,et al.  Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. , 2008, The New England journal of medicine.

[8]  V. Calvez,et al.  Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro , 2008, Antimicrobial Agents and Chemotherapy.

[9]  M. Markowitz,et al.  Raltegravir (MK-0518): an integrase inhibitor for the treatment of HIV-1. , 2007, Drugs of today.

[10]  Brian P. Kearney,et al.  Antiviral Activity, Pharmacokinetics, and Dose Response of the HIV-1 Integrase Inhibitor GS-9137 (JTK-303) in Treatment-Naive and Treatment-Experienced Patients , 2006, Journal of acquired immune deficiency syndromes.

[11]  W. Robinson,et al.  Preliminary Mapping of a Putative Inhibitor-Binding Pocket for Human Immunodeficiency Virus Type 1 Integrase Inhibitors , 2006, Antimicrobial Agents and Chemotherapy.

[12]  Mark Embrey,et al.  A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[13]  M. Greenberg,et al.  Resistance to enfuvirtide, the first HIV fusion inhibitor. , 2004, The Journal of antimicrobial chemotherapy.

[14]  E. De Clercq,et al.  Development of Resistance against Diketo Derivatives of Human Immunodeficiency Virus Type 1 by Progressive Accumulation of Integrase Mutations , 2003, Journal of Virology.

[15]  Linghang Zhuang,et al.  Design and synthesis of 8-hydroxy-[1,6]naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells. , 2003, Journal of medicinal chemistry.

[16]  E. De Clercq,et al.  Inhibition of Human Immunodeficiency Virus Type 1 Integration by Diketo Derivatives , 2002, Antimicrobial Agents and Chemotherapy.

[17]  Christos J. Petropoulos,et al.  A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1 , 2000, Antimicrobial Agents and Chemotherapy.

[18]  J A Grobler,et al.  Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. , 2000, Science.

[19]  F. Bushman,et al.  Identification of discrete functional domains of HIV‐1 integrase and their organization within an active multimeric complex. , 1993, The EMBO journal.

[20]  Robert Craigie,et al.  HIV-1 DNA integration: Mechanism of viral DNA cleavage and DNA strand transfer , 1991, Cell.

[21]  F. Bushman,et al.  Activities of human immunodeficiency virus (HIV) integration protein in vitro: specific cleavage and integration of HIV DNA. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[22]  F. Bushman,et al.  Retroviral DNA integration directed by HIV integration protein in vitro. , 1990, Science.

[23]  R. Craigie,et al.  HIV integrase structure and function. , 1999, Advances in virus research.

[24]  E. Asante-Appiah,et al.  HIV-1 integrase: structural organization, conformational changes, and catalysis. , 1999, Advances in virus research.